These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 15868140)

  • 1. Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment.
    Moskowitz SM; Gibson RL; Effmann EL
    Pediatr Radiol; 2005 Aug; 35(8):739-57. PubMed ID: 15868140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating the Airway Consequences of Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction.
    Toprak D; Davis C; Rosenfeld M
    Semin Respir Crit Care Med; 2019 Dec; 40(6):751-761. PubMed ID: 31659732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular heterogeneity of CFTR expression and function in the lung: implications for gene therapy of cystic fibrosis.
    Jiang Q; Engelhardt JF
    Eur J Hum Genet; 1998 Jan; 6(1):12-31. PubMed ID: 9781011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggregates of mutant CFTR fragments in airway epithelial cells of CF lungs: new pathologic observations.
    Du K; Karp PH; Ackerley C; Zabner J; Keshavjee S; Cutz E; Yeger H
    J Cyst Fibros; 2015 Mar; 14(2):182-93. PubMed ID: 25453871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [On the way to gene therapy in cystic fibrosis].
    Norek A; Bal J
    Med Wieku Rozwoj; 2006; 10(1 Pt 2):247-74. PubMed ID: 17028392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease.
    Bonadia LC; de Lima Marson FA; Ribeiro JD; Paschoal IA; Pereira MC; Ribeiro AF; Bertuzzo CS
    Gene; 2014 May; 540(2):183-90. PubMed ID: 24583165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CFTR: cystic fibrosis and beyond.
    Mall MA; Hartl D
    Eur Respir J; 2014 Oct; 44(4):1042-54. PubMed ID: 24925916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection.
    Ziedalski TM; Kao PN; Henig NR; Jacobs SS; Ruoss SJ
    Chest; 2006 Oct; 130(4):995-1002. PubMed ID: 17035430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?
    Büscher R; Grasemann H
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Nov; 374(2):65-77. PubMed ID: 17033796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy for the respiratory manifestations of cystic fibrosis.
    Korst RJ; McElvaney NG; Chu CS; Rosenfeld MA; Mastrangeli A; Hay J; Brody SL; Eissa NT; Danel C; Jaffe HA
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S75-87. PubMed ID: 7533609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. The University of North Carolina at Chapel Hill.
    Boucher RC; Knowles MR; Johnson LG; Olsen JC; Pickles R; Wilson JM; Engelhardt J; Yang Y; Grossman M
    Hum Gene Ther; 1994 May; 5(5):615-39. PubMed ID: 7519885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic fibrosis transmembrane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy.
    Bangel-Ruland N; Tomczak K; Fernández Fernández E; Leier G; Leciejewski B; Rudolph C; Rosenecker J; Weber WM
    J Gene Med; 2013; 15(11-12):414-26. PubMed ID: 24123772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease.
    Aitken ML; Moss RB; Waltz DA; Dovey ME; Tonelli MR; McNamara SC; Gibson RL; Ramsey BW; Carter BJ; Reynolds TC
    Hum Gene Ther; 2001 Oct; 12(15):1907-16. PubMed ID: 11589832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatments targeting the basic defects in cystic fibrosis.
    Fajac I; Wainwright CE
    Presse Med; 2017 Jun; 46(6 Pt 2):e165-e175. PubMed ID: 28554723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of defective cystic fibrosis airway epithelial wound repair after CFTR rescue.
    Trinh NT; Bardou O; Privé A; Maillé E; Adam D; Lingée S; Ferraro P; Desrosiers MY; Coraux C; Brochiero E
    Eur Respir J; 2012 Dec; 40(6):1390-400. PubMed ID: 22496330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cystic fibrosis transmembrane conductance regulator (CFTR) gene: mutations and clinical phenotypes].
    Schwartz M
    Ugeskr Laeger; 2003 Feb; 165(9):912-6. PubMed ID: 12661515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of the cystic fibrosis gene in the lungs].
    Heijerman HG; de Jonge HR
    Ned Tijdschr Geneeskd; 2004 Apr; 148(17):816-9. PubMed ID: 15141646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT.
    Mott LS; Park J; Murray CP; Gangell CL; de Klerk NH; Robinson PJ; Robertson CF; Ranganathan SC; Sly PD; Stick SM;
    Thorax; 2012 Jun; 67(6):509-16. PubMed ID: 22201161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA class II polymorphism in cystic fibrosis. A possible modifier of pulmonary phenotype.
    Aron Y; Polla BS; Bienvenu T; Dall'ava J; Dusser D; Hubert D
    Am J Respir Crit Care Med; 1999 May; 159(5 Pt 1):1464-8. PubMed ID: 10228112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.